ILEX Oncology Appoints Ze'ev Shaked, Ph.D. to Lead
Company's Product Development Effort
SAN ANTONIO--(BUSINESS WIRE)--July 19, 2000--ILEX(TM)Oncology, Inc. (Nasdaq:ILXO - news) today
announced the appointment of Ze'ev Shaked, Ph.D. as President of ILEX Products, Inc., a wholly owned subsidiary of ILEX
Oncology. In this position, Dr. Shaked will be responsible for the overall development of the company's proprietary pipeline of
anti-cancer drugs.
A recognized pioneer in the biotechnology industry, Dr. Shaked, 54, has more than 20 years experience in the development of
protein biotherapeutics, synthetic peptides and conventional compounds, including oncology, autoimmune, wound healing,
growth factor and allergy products. He brings extensive senior management, research and product development experience to
ILEX through his previous roles with ImmuLogic Pharmaceutical Corporation, Berlex Biosciences, Inc., Triton Biosciences,
Inc., Codon and Cetus Corporation.
Dr. Shaked has published numerous scientific papers, conducted seminars and workshops, and holds a number of patents. He
earned his doctorate in applied biochemistry and organic chemistry from the Massachusetts Institute of Technology and
undergraduate degrees in chemistry and physics from The Hebrew University of Jerusalem.
``As a consultant to ILEX over the past five years, Ze'ev has worked closely with us on the development of several of our
leading compounds, including CAMPATH®, as well as adding significant value to our emerging angiogenesis inhibitor
platform,'' said Richard Love, ILEX President and Chief Executive Officer. ``He is an accomplished executive with a
broad-based drug development, technical and regulatory background. His experience in all phases of pharmaceutical
development from discovery research through drug approval and product launch will be invaluable to ILEX as we further
develop our portfolio of oncology compounds. We are excited to have him join us in this important leadership role.''
ILEX Products, Inc. is developing a robust pipeline of anti-cancer drugs in all phases of clinical development and maintains an
active in-licensing program for complementary products and technologies. Unlike early stage drug discovery companies
dependent on a single technology, ILEX focuses on the treatment and prevention of cancer and pursues any promising
technology.
About ILEX Oncology
ILEX Oncology, Inc. is a drug development company focused predominantly on the accelerated development of drugs for the
treatment and prevention of cancer. The company does this in two ways: by advancing a diversified portfolio of anti-cancer
drugs through its ILEX Products subsidiary, and, by offering drug development services on a contract basis to pharmaceutical
and biotech companies through its ILEX Oncology Services subsidiary. These complementary businesses draw from the
company's core relationships with international oncology experts, strategic alliances providing unparalleled access to patient
recruitment for clinical trials, and simultaneous European and US drug development and approval capabilities.
Certain statements contained herein are ``forward-looking'' statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially
from those expressed or implied by such forward-looking statements include, but are not limited to, the early stage of ILEX's
compounds under development; risks in technology and product development; failure to successfully complete clinical trials;
failure to receive market clearance from regulatory agencies; dependence on third parties and partners and those risks
described in ILEX's Form S-3 filed March 8, 2000 (Commission file No. 333-32000), and ILEX's Annual Report on Form
10-K for the year ended December 31, 1999, and in other filings made by ILEX with the SEC. ILEX disclaims any obligation
to update these forward-looking statements.
